Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Stephens Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its target price hoisted by equities research analysts at Stephens from $95.00 to $100.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ target price points to a potential upside of 15.81% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on KYMR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. HC Wainwright lifted their target price on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Guggenheim began coverage on shares of Kymera Therapeutics in a research note on Monday, November 3rd. They set a “buy” rating and a $90.00 price target for the company. Morgan Stanley restated an “overweight” rating and issued a $123.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Leerink Partners upped their target price on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $86.35 on Monday. The company has a fifty day moving average of $78.69 and a two-hundred day moving average of $66.27. The company has a market capitalization of $7.05 billion, a PE ratio of -23.46 and a beta of 2.20. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.88) EPS. On average, research analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 2,005,813 shares of the stock in a transaction on Thursday, December 11th. The stock was acquired at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the acquisition, the director directly owned 7,955,916 shares in the company, valued at $684,208,776. This represents a 33.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 450,895 shares of company stock valued at $40,486,151. Corporate insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP boosted its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the period. Finally, Holocene Advisors LP purchased a new position in shares of Kymera Therapeutics in the 3rd quarter valued at about $47,563,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.